NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday that its second quarter revenues for fiscal year 2015 declined 10 percent year over year.

Myriad also substantially lowered its guidance for Fiscal Year 2015, leading to a drop in its stock on Wednesday morning.

For the three months ended Dec. 31, the Salt Lake City-based molecular diagnostics firm had total revenues of $184.4 million compared to revenues of $204.1 million in Q2 2014. The revenues beat the consensus Wall Street estimate of $183.4 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.